Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
We established a mouse model of secondary pneumococcal pneumonia after influenza virus infection and investigated the efficacy of several quinolones against pneumonia in this model. Gatifloxacin exhibited the highest efficacy among the quinolones examined and is probably useful for the treatment of secondary bacterial pneumonia.
Hayashi
Katsuhiko
K
Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Shimotsuga, Tochigi 329-0114, Japan.
Kadowaki
Shin-etsu
SE
Takei
Masaya
M
Fukuda
Hideyuki
H
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D000077734:Gatifloxacin; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D015242:Ofloxacin / Q000627:therapeutic use*; D009976:Orthomyxoviridae Infections / Q000150:complications*; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy* / Q000473:pathology
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D002939:Ciprofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin